The market for Urinary Tract Infections (UTI) is a well- established space, flooding with the numerous treatment options ranging from Home remedies, Alternative medicines to Antibiotics. Due to the growing prevalence of UTI, the market for UTI Treatment is escalating exponentially.
Acknowledging the exponential growth, the market is observing currently; Market Research Future (MRFR) in its recently published study report asserts that the UTI Treatment market is forecasted to reach USD 9.89 Bn. by 2023 with a CAGR of 3.6 % from 2017 to 2023.
In addition to the growing incidences of urinary tract infections, factors impacting the market growth include the rise in hospital-borne infections or nosocomial infections, childbirth, old age, obesity, and the growing health awareness, especially towards women health. However, the rising cases of UTI associated with the usages of the catheter are considered as the largest risk factor supporting the market growth.
On the flip side, factors such as incidents of drug resistance, and large unmet clinical needs are expected to obstruct the market growth. Nevertheless, increasing incidence of chronic diseases resulting in catheter use and low immunity etc. are expected to support the market growth.
Leveraging to the modern age, people have adopted unhealthy lifestyles which mirrors the prevalence of damaged immune system and various disorders. Immense of stress, lack of quality sleep, inadequate & improper diet and sedentary lifestyle are fuelling the immunodeficiency disorders. All these factors commutatively fuel the occurrences of UTI.
Request Free Sample Copy at: https://www.marketresearchfuture.com/sample_request/3146
Global UTI Treatment Market - Segmentations
The MRFR analysis is segmented into four key dynamics for the convenience of understanding;
By Drug Class : Comprises - Quinolones, Aminoglycosides, β-lactam, and Azoles among others.
By Clinical Indications : Urethritis, Cystitis, and Pyelonephritis among others.
By End-Users : Hospitals and Self-administered among others.
By Regions : North America, Europe, APAC and the Rest-of-the-World.
The subsegment Quinolones accounts for almost 45% of market share whereas the subsegment Aminoglycosides segment holds the second-largest market share by drug class in the global UTI treatment market.
Global UTI Treatment Market - Regional Landscape
North America region accounts for the leading market for UTI Treatment, acquiring the largest market share, globally. Various factors substantiating the market growth include the availability of specialized treatment centers, the presence numerous players, solid support from the government and private entities, improved patients experience with high quality and low-cost services in the region.
However, the regulatory changes in the US such as the implementation of Affordable Care Act and Hospital Readmissions Reduction Program alongside the Medicare initiative to penalize unnecessary patient readmissions is expected to take a toll on the UTI treatment market in the US.
Europe & Asia Pacific region accounts for the second & third largest market respectively in the global UTI Treatment market.
Whereas, the increasing patient pool coupled with the demand for more treatment centers drive the market growth in the APAC region. Owing to the rising funding and proliferating infrastructures for healthcare, mainly in countries like China and India the Asia Pacific market is emerging as one of the lucrative markets, globally.
Global UTI Treatment Market - Competitive Landscape
The global UTI Treatment market is fragmented with a large number of players. Drug class - Quinolones is curtailing the product development strategy with its efficiency and efficacy. However, the increasing cases of drug resistance have opened doors for new drug development, providing scope for a new market leader. The rise of spurious and counterfeit medicines has reduced the total market revenues and at the same time displaced standard drugs off the market.
Key Players:
Some of the leaders driving the global UIT market include Novartis AG, Bayer AG, Pfizer Inc., AstraZeneca, F. Hoffmann-La Roche Ltd, Cipla Inc., Johnson & Johnson, GlaxoSmithKline, and Dr. Reddy’s Laboratories Ltd.
Industry/Innovations/Related News:
August 8, 2018 - Paratek Pharmaceuticals, Inc. (US) announced the approval from the Antimicrobials Drug Advisory Committee of the U.S. Food and Drug Administration for its Omadacycline for the treatment of severe bacterial skin and skin structure infections (ABSSSI), community-acquired bacterial pneumonia (CABP) and urinary tract infections (UTI).
Administered through both, intravenous (IV) and oral formulations, the new medicine omadacycline is a modernized tetracycline being developed as a broad-spectrum antibiotic for the treatment of serious community-acquired infections.
Browse Detailed TOC with COVID-19 Impact Analysis at: https://www.marketresearchfuture.com/reports/uti-treatment-market-3146
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), & Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients.
Contact:
Akash Anand
Market Research Future
+1 646 845 9312
Email: [email protected]
